Clinical Trial Update: Denosumab Strategy for Liver Cancer With Bone Metastases [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating denosumab as a strategy for hepatocellular carcinoma with bone metastases. The study is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases
• Hepatocellular Carcinoma

Drugs mentioned

• Denosumab (denosumab)

Snippet

Sponsor: Tongji Hospital | Conditions: Hepatocellular Carcinoma (HCC), Bone Metastases | Phase 2 | Status: NOT_YET_RECRUITING